UNSPSC 51294201: Bazinaprine

This classification denotes a monoamine oxidase inhibitor and antidepressant agent with the molecular formula C17H19N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NU8Y4C529J, chemically known as 4-pyridazinecarbonitrile, 3-((2-(4-morpholinyl)ethyl)amino)-6-phenyl- but generally known as bazinaprine, which bears US NIH Compound Identifier 72119. European Medicines Agency schedules Bazinaprine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05672MIG.

UNSPSC 51294201 Bazinaprine, a Commodity code, shows minimal direct relevance to recent state and local procurement activity. The code nominally describes a specific pharmaceutical ingredient, but the three recent opportunities tagged under it—naloxone procurement, a Texas pharmacy benefit initiative RFI, and a Minnesota cooperative purchasing agreement for generic multi-source pharmaceuticals and OTC products—do not center on bazinaprine or closely related compounds. Seminole County, Florida's IFB for naloxone and drug deactivation systems, the Texas Health and Human Services Commission's exploratory RFI on direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance's (MMCAP) RFP for generic pharmaceuticals represent broader pharmacy and public health supply categories rather than the narrow pharmaceutical-ingredient scope the code suggests. The issuing bodies span county health departments, state HHS agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions, but the actual scope of work involves finished pharmaceutical products, OTC items, and supply-chain contracting rather than active pharmaceutical ingredients or intermediates.

Activity appears concentrated in Florida and Minnesota through identifiable recent solicitations, with Texas also represented through the HHS RFI. Seminole County's IFB (due July 26, 2023) sought quarterly deliveries of 1,900 units of naloxone and 800 safe drug deactivation systems annually; the MMCAP RFP (due March 26, 2026) targeted generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities; and the Texas HHS Commission's RFI (posted April 3, 2026) gathered market intelligence on direct-to-manufacturer pharmacy contracting models. The mismatch between the code's pharmaceutical-ingredient nomenclature and the actual procurement activity—which centers on finished medications, drug safety systems, and supply-chain coordination—suggests this code has limited relevance to firms focused on active pharmaceutical ingredient supply or that state and local procurement systems may be applying the code incorrectly to broader pharmaceutical purchasing categories.